Online inquiry

IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6632MR)

This product GTTS-WQ6632MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6632MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9855MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ1467MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ13741MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ563MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ8764MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ6473MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ9569MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15991MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW